Related Experiment Video
Updated: Jul 12, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Vaccines to treat cancer--an old approach whose time has arrived
Karl Erik Hellstrom1, Ingegerd Hellstrom
1Department of Pathology, Harborview Medical Center, University of Washington, Seattle, Washington 98104-2499, USA. hellsk@u.washington.edu
Abstract:
There are extensive DNA changes in tumor cells and the genes of tumor cells continuously mutate at a high rate. While this can provide therapeutic targets, it makes it unlikely that an agent that is selective for a single target will work against all cells in a tumor. However, it may be possible to use tumor epitopes as sentinels to engage adaptive and innate immunological mechanisms and create a tumor destructive environment effective also against variant cells that have lost a given antigen or their ability to present it. We hypothesize that therapeutic tumor vaccines, in combination with the targeting, to tumors, of costimulatory molecules such as anti-CD137scFv, or lymphokines such as GMCSF, will expand anti-tumor responses for therapeutic benefit when used as an adjunct to surgery and chemotherapy.
Insights
Tumor vaccines combined with immune-stimulating agents can overcome tumor cell mutations. This approach engages the immune system to destroy cancer cells, even variants, offering therapeutic benefits alongside traditional treatments.
Area of Science:
- Oncology
- Immunology
- Cancer Genetics
Background:
- Tumor cells exhibit extensive DNA changes and high mutation rates, complicating single-target therapies.
- Tumor heterogeneity poses a challenge for treatments relying on specific antigens.
Purpose of the Study:
- To explore a strategy using tumor epitopes to activate immune responses against heterogeneous tumors.
- To investigate the potential of combining therapeutic tumor vaccines with immune-modulating agents.
Main Methods:
- Utilizing tumor epitopes as sentinels to engage adaptive and innate immunity.
- Administering therapeutic tumor vaccines.
- Targeting tumors with costimulatory molecules (e.g., anti-CD137scFv) or lymphokines (e.g., GMCSF).
Main Results:
- The proposed combination therapy aims to expand anti-tumor immune responses.
- This approach is hypothesized to be effective against tumor variants lacking specific antigens or antigen presentation capabilities.
Conclusions:
- Therapeutic tumor vaccines combined with immune-targeting agents show promise.
- This strategy could provide a more robust anti-tumor environment, effective even against antigen-loss variants, as an adjunct to surgery and chemotherapy.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...